icon-folder.gif   Conference Reports for NATAP  
 
  EASL - The International Liver Congress 2014
49th Annual Meeting of the European
Association for the Study of the Liver
London, United Kingdom  April 9-13
Back grey_arrow_rt.gif
 
 
 
Resource Utilization During Hepatitis C Treatment With Boceprevir- or Telaprevir-Based Triple Therapy vs Dual Therapy In A Large Health Maintenance Organization - low treatment rates & high resource utilization rate too with IFN-based therapies boceprevir or telaprevir or INF-based Double Therapy In A Large Health Maintenance Organization
 
 
  in light of the trend to prioritize treatment for advanced disease this study highlights the resources being devoted to treatment with previous therapies: Peg/Rbv, telaprevir+PR, BOC+PR and the authors conclude:
 
In conclusion, health care resource utilization was significantly increased with triple vs dual therapy. Future treatment may require less health care resources due to increased potency, expected shorter treatment duration and better side effect profiles.
 
and the dollar costs associated:

EASL1.gif

and this study demonstrates the leaps the new interferon-free therapies bring, and the the limitations of previous Peg/Rbv therapy with telaprevir or boceprevir or before with PR alone-
Only approximately 8-12% of patients with chronic HCV infection received anti-HCV treatment both in the pre-PI as well as in post-PI era.
 
Low treatment rates and suboptimal treatment completion rates to HCV therapy: A real world analysis of a large US cohort - (05/05/14)
 
Resource Utilization During Hepatitis C Treatment With Boceprevir- or Telaprevir-Based Triple Therapy vs Dual Therapy In A Large Health Maintenance Organization
 
http://www.natap.org/2014/DDW/DDW_04.htm
 
Reported by Jules Levin
EASL 2014 London, UK
 
Lisa M. Nyberg1, Kevin M. Chiang2, Yi-Lin Wu2, Anders H. Nyberg1, Zobair M. Younossi3, T. Craig Cheetham2
1Hepatology Research, Kaiser Permanente, San Diego, CA, United States; 2Pharmacy Analytical Services, Kaiser Permanente, Downey, CA, United States; 3Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, United States.

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif